Alimentary Pharmacology & Therapeutics

Papers
(The H4-Index of Alimentary Pharmacology & Therapeutics is 42. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
156
Letter: Positivity of High‐Sensitivity HBsAg Test Was Significantly Associated With Poor Prognosis in Patients With Non‐HBV‐Related HCC154
Letter: Gut microbiota—An overlooked therapeutic target in the prevention of post‐operative recurrence of Crohn's disease154
AP&T: Editors' Declarations of Interest120
Safety of an investigational formulation of budesonide (budesonide oral suspension) for eosinophilic oesophagitis: an integrated safety analysis of six phase 1–3 clinical trials93
87
Issue Information76
Letter: Real‐Life Evaluation of Effectiveness of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease Emphasises Importance of Appropriate Patient Selection and Centre Expertise—Authors' Rep75
Letter: time to consider Pneumocystis jirovecii pneumonia prophylaxis in treatment of autoimmune hepatitis70
Letter: Potential confounders might exaggerate the risk of rheumatoid arthritis in patients with microscopic colitis66
Issue Information65
Clinical Trial: Effect of Abdominal Vibration Combined With Walking Exercise Programme on Bowel Preparation in Older Patients With Constipation64
64
Letter: Allostatic load—A potential key in the development of inflammatory bowel disease62
Editorial: The future of managing drug induced liver injury61
Positivity of high‐sensitivity HBsAg test, not previous HBV infection, indicates poor prognosis in patients with non‐HBV‐related HCC60
Editorial: STAT3 phosphorylation for tofacitinib monitoring in ulcerative colitis—a step towards precision medicine?59
Letter: Elderly onset inflammatory bowel disease—Treat to target approach is still warranted59
Editorial: switching to tenofovir alafenamide monotherapy is effective and safe for other nucleos(t)ide analogues‐treated patients with chronic hepatitis B58
Editorial: Updated epidemiology of steatotic liver disease in people withHIVin the United States—Authors' reply58
Editorial: tradipitant has promise for treating gastroparesis but leaves gastric function alone—authors’ reply58
Editorial: rectal hyposensitivity in patients with hypermobile Ehlers‐Danlos syndrome and constipation—authors' reply58
Editorial: ustekinumab during pregnancy ‐ reassuring but still not enough55
Liver resection versus microwave ablation for hepatocellular carcinoma in ideal candidates for ablation per Barcelona Clinic Liver Cancer staging: a propensity score matching and inverse probability o54
Editorial: Plants against animals52
Editorial: biomarkers for alcohol‐related liver fibrosis—almost there?52
Editorial: risk of pneumonia in IBD—reading between the lines!51
Letter: is wireless oesophageal pH monitoring the best technique to evaluate night‐time reflux?51
Letter: ductular reaction is a risk factor for prognosis of chronic hepatitis B complicated with non‐alcoholic fatty liver disease50
Letter: Ozanimod and latent tuberculosis49
Letter: Critical appraisal of biologic therapy in early ulcerative colitis management—Addressing study limitations and the role of psychological resilience—Authors' reply47
Editorial: clinical outcomes in lean NAFLD – the devil is in the details. Authors' reply46
Editorial: concurrence of coeliac disease with inflammatory bowel disease – is big data the final arbiter? Authors' reply46
Editorial: dietary interventions to understand and treat primary sclerosing cholangitis—is gluten‐free diet a starting point?46
Editorial: coeliac disease follow‐up guided by gluten immunogenic peptides—are we there yet? Authors' reply46
Editorial: Advanced glycation end products ‐ a dietary culprit for IBD in the genetically susceptible?45
Letter: practical considerations for nonselective beta‐blocker therapy in portal hypertension45
Editorial: Can we predict or not predict response to hypnotherapy? That is the question44
Editorial: Assessing advanced fibrosis in metabolic‐associated steatotic liver disease—TheMAFLDfibrosis score44
First in human randomised trial of J2H‐1702: A novel 11β‐hydroxysteroid dehydrogenase type 1 inhibitor for non‐alcoholic steatohepatitis treatment43
Low socioeconomic status exacerbates unmet health‐related needs in patients with autoimmune hepatitis43
Diagnostic Accuracy of an Add‐On, Blood‐Based Screening Test for Colorectal Cancer in Two Established Screening Programmes42
Editorial: Inflammatory Bowel Disease and Dietary Emulsifiers—A Conundrum That Continues. Authors' Reply42
0.076103925704956